Lyra Therapeutics 

Yahoo Finance • last year

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lyra Therapeutics, Inc. (NASDAQ: LYRA) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Lyra Therapeutics, Inc. (NASDAQ: LYRA) (“Lyra”) on behalf of the company’s investors. Since August 2022, shares of Lyra’s common stock ha... Full story

Yahoo Finance • last year

Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

– Additional Phase 2 BEACON trial CT scan data demonstrated statistically significant improvement in sinus opacification with LYR-220 and provided radiological evidence of improvement in chronic rhinosinusitis (CRS) patients who have had p... Full story

Yahoo Finance • last year

Lyra Therapeutics to Participate in Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announc... Full story

Yahoo Finance • last year

INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Lyra Therapeutics, Inc.; Urges Lyra Stockholders to Contact Abbott Cooper Regarding Their Legal Rights

STAMFORD, Conn., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) on behalf of the Company’s investors. The investigation seeks to determine whether L... Full story

Yahoo Finance • last year

Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal Officer

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinu... Full story

Yahoo Finance • last year

Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery

Study demonstrates statistically significant and clinically relevant improvements in 3 Cardinal Symptoms and SNOT-22 scores at 24 weeks Statistically significant improvements in efficacy were observed as early as 2 weeks Primary endpoint... Full story

Yahoo Finance • last year

Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis

WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment o... Full story

Yahoo Finance • last year

Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference

WATERTOWN, Mass., July 13, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS),... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment, with Data Expected in 1H 2024 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference

WATERTOWN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of patients with chronic rhinosinusitis (CRS),... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis

WATERTOWN, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosin... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

-- ENLIGHTEN I Pivotal Phase 3 Trial of LYR-210 in Pre-Surgical Chronic Rhinosinusitis (CRS) on Track to Complete Enrollment in mid-2023 -- -- Data from BEACON Phase 2 Trial of LYR-220 in Post-Surgical CRS Anticipated Q4 2023 -- -- Advan... Full story

Yahoo Finance • 2 years ago

Estimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA)

Key Insights Lyra Therapeutics' estimated fair value is US$1.98 based on 2 Stage Free Cash Flow to Equity Lyra Therapeutics' US$2.03 share price indicates it is trading at similar levels as its fair value estimate The US$16.75 analyst pri... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusiti... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

-- Topline Results Expected in Q4 2023 -- -- LYR-220 is Lyra’s Second Product Candidate, Following LYR-210 in Surgically-Naïve CRS patients -- WATERTOWN, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (the Company or Lyra), a clinical-stage biotechnology company developing therapies for the localized treatment of patients with chronic rhinosinus... Full story

Yahoo Finance • 2 years ago

Lyra Therapeutics to Present at Upcoming Investor Conferences

WATERTOWN, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage biotechnology company developing novel, integrated drug and delivery solutions for the localized treatment of patients with chro... Full story

Yahoo Finance • 3 years ago

Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

In April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024 Pivotal ENLIGHTEN Phase 3 clinical p... Full story